Lifecare boosts Bergen output to 19 implants passing qualification tests

• Lifecare reported 19 glucose-monitoring implants passed qualification testing in Bergen within less than one month, marking progress toward repeatable in-house production.
• The initial batch announced September 29, 2026, comprised three implants, with two passing testing.
• Nine qualified implants shipped to Bristol October 20 for final testing; eight more passed qualification testing in Bergen October 24.
• Production moved to new Bergen facilities following the Ocean Tunicell acquisition; transferring final testing from Bristol will consolidate manufacturing there.
• Increased staffing in Bristol expands laboratory capacity, with the site increasingly focused on glucose-sensing chemistry optimization and broader sensing technology development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecare ASA published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202610260200OSLOBORSNEWS__EN_FD7E641BD913B1A81212B2546C7C0A5), on October 26, 2026, and is solely responsible for the information contained therein.